Business Context and Reporting Period
Silexion Therapeutics Corp (SLXN), a Cayman Islands-based emerging growth company, filed this Form 8-K on November 1, 2024, regarding an event dated October 29, 2024. The Company is listed on The Nasdaq Stock Market LLC under the symbols SLXN (Ordinary Shares) and SLXNW (Warrants).
Key Financial Metrics
This filing is a current report regarding listing status and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Listing Status
On October 29, 2024, the Company received a deficiency letter from Nasdaq stating that its ordinary share closing bid price had been below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The deficiency has no immediate effect on trading, but the Company must regain compliance by April 28, 2025.
Outlook, Management Commentary, and Risks
- Compliance Timeline: The Company has 180 calendar days (until April 28, 2025) to restore the bid price to $1.00 or higher for 10 consecutive business days.
- Proposed Remedy: Management plans to hold an extraordinary general meeting on November 12, 2024, to seek shareholder approval for a reverse share split with a ratio between 1-for-10 and 1-for-20.
- Contingencies: If compliance is not achieved by the initial deadline, the Company may apply for a second 180-day period to transfer to the Nasdaq Capital Market, contingent on meeting other listing standards and executing a reverse split.
- Risks: There is no assurance that the reverse split will be approved by shareholders, that it will successfully cure the deficiency, or that Nasdaq will grant a second compliance period. Failure to comply could result in delisting.
Investor Verification Checklist
- Verify the outcome of the extraordinary general meeting scheduled for November 12, 2024, regarding the proposed reverse share split.
- Monitor the daily closing bid price of SLXN to track progress toward the $1.00 threshold.
- Confirm whether the Company submits an application to transfer to the Nasdaq Capital Market if the initial compliance period expires without success.
- Review any subsequent filings for updates on the Nasdaq deficiency status or potential delisting notices.